Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IQVIA Holdings Inc. (IQV)
USD207.55
-0.30 (-0.14%)
US NYSE S&P 500
Healthcare Medical - Diagnostics & Research
Address
2400 Ellis Road 27703
Durham, NC, US
Durham, NC, US
CEO
Ari Bousbib
Website
iqvia.com
IPO
2013-05-09
CIK 1478242 ISIN US46266C1053
Also trades on
London Stock Exchange · 0JDM.L (USD)
New York Stock Exchange · IQV (USD)
Description
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
News Sentiment (7d)
Based on only 1 article — low confidence
- Here's Why IQVIA Holdings (IQV) is a Strong Value Stock Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 2017-08-28 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD207.55
-0.30 (-0.14%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.22
Float Shares
161.24M
Free Float %
95.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.89% | -2.42% | +3.71% | +2.78% | -21.43% | -23.01% | +11.16% | -7.77% | -23.88% | +165.73% | +312.13% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (44 ratings, all time)
Buy
Price Targets & DCF
Current price
207.55
Low
185.00
-10.9%
Consensus
223.75
+7.8%
Median
222.50
+7.2%
High
250.00
+20.5%
DCF (Unlevered)
300.62
+44.8%
DCF (Levered)
269.60
+29.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
91% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 17 | 0 |
| Hold | 2 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
185.00
-10.9%
|
| Last Quarter | 8 |
225.63
+8.7%
|
| Last Year | 25 |
231.20
+11.4%
|
| All Time | 52 |
249.76
+20.3%
|
Quality scores
Altman Z-Score
1.87
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+5.9% Q1'26: +8.4% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+4.7% Q1'26: +15.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+12.3% Q1'26: +14.9% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+14.2% ★ Q1'26: +12.4% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+9.5% ★ Q1'26: +26.0% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-5.4% ★ Q1'26: -4.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×4.67× Q1'26: 0.65× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 14 EPS Ana. |
Dec 2027 16 Rev. Ana. 15 EPS Ana. |
Dec 2028 14 Rev. Ana. 8 EPS Ana. |
Dec 2029 9 Rev. Ana. 6 EPS Ana. |
Dec 2030 13 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.46B
est: 5.14B (+6.2%)
|
5.74B
est: 4.33B (+32.6%)
|
6.82B
est: 5.38B (+26.8%)
|
9.70B
est: 8.04B (+20.7%)
|
10.41B
est: 10.35B (+0.6%)
|
11.09B
est: 11.04B (+0.5%)
|
11.36B
est: 11.20B (+1.4%)
|
13.87B
est: 13.83B (+0.3%)
|
14.41B
est: 14.38B (+0.2%)
|
14.98B
est: 15.16B (-1.1%)
|
15.41B
est: 15.38B (+0.2%)
|
16.31B
est: 16.18B (+0.8%)
|
17.28B
17.21B – 17.39B
+6.8% YoY
|
18.26B
17.85B – 18.77B
+5.7% YoY
|
19.28B
19.23B – 19.33B
+5.6% YoY
|
20.48B
20.27B – 20.89B
+6.2% YoY
|
21.75B
21.51B – 22.17B
+6.2% YoY
|
| EBITDA |
723.00M
est: 681.37M (+6.1%)
|
768.00M
est: 712.44M (+7.8%)
|
849.00M
est: 866.00M (-2.0%)
|
1.65B
est: 1.60B (+2.9%)
|
1.88B
est: 1.80B (+4.3%)
|
2.00B
est: 1.92B (+4.1%)
|
2.08B
est: 1.94B (+7.1%)
|
2.77B
est: 2.57B (+7.7%)
|
2.91B
est: 2.89B (+0.5%)
|
3.26B
est: 3.20B (+1.8%)
|
3.45B
est: 3.25B (+6.4%)
|
3.46B
est: 3.42B (+1.4%)
|
3.65B
3.63B – 3.67B
+6.8% YoY
|
3.85B
3.77B – 3.96B
+5.7% YoY
|
4.07B
4.06B – 4.08B
+5.6% YoY
|
4.32B
4.28B – 4.41B
+6.2% YoY
|
4.59B
4.54B – 4.68B
+6.2% YoY
|
| EBIT |
602.00M
est: 552.79M (+8.9%)
|
640.00M
est: 593.55M (+7.8%)
|
560.00M
est: 623.53M (-10.2%)
|
640.00M
est: 686.77M (-6.8%)
|
742.00M
est: 714.49M (+3.9%)
|
799.00M
est: 763.10M (+4.7%)
|
789.00M
est: 694.55M (+13.6%)
|
1.50B
est: 1.29B (+16.8%)
|
1.78B
est: 1.72B (+3.1%)
|
2.13B
est: 2.02B (+5.2%)
|
2.34B
est: 2.05B (+13.8%)
|
2.32B
est: 2.16B (+7.3%)
|
2.31B
2.30B – 2.32B
+6.8% YoY
|
2.44B
2.39B – 2.51B
+5.7% YoY
|
2.58B
2.57B – 2.58B
+5.6% YoY
|
2.74B
2.71B – 2.79B
+6.2% YoY
|
2.91B
2.87B – 2.96B
+6.2% YoY
|
| Net Income |
356.38M
est: 333.45M (+6.9%)
|
387.21M
est: 354.81M (+9.1%)
|
115.00M
est: 114.15M (+0.7%)
|
1.31B
est: 1.25B (+4.7%)
|
259.00M
est: 249.52M (+3.8%)
|
191.00M
est: 187.35M (+2.0%)
|
279.00M
est: 268.05M (+4.1%)
|
966.00M
est: 896.18M (+7.8%)
|
1.09B
est: 1.17B (-7.0%)
|
1.36B
est: 1.36B (-0.3%)
|
1.37B
est: 1.93B (-28.9%)
|
1.36B
est: 2.07B (-34.2%)
|
2.21B
2.19B – 2.24B
+7.2% YoY
|
2.48B
2.37B – 2.58B
+11.8% YoY
|
2.77B
2.28B – 3.25B
+11.8% YoY
|
3.07B
3.03B – 3.15B
+10.9% YoY
|
3.40B
3.36B – 3.49B
+11.0% YoY
|
| SGA |
882.34M
est: 825.48M (+6.9%)
|
920.99M
est: 846.52M (+8.8%)
|
1.01B
est: 1.27B (-20.2%)
|
1.61B
est: 2.50B (-35.8%)
|
1.72B
est: 2.75B (-37.7%)
|
1.73B
est: 2.88B (-39.9%)
|
1.79B
est: 1.99B (-10.2%)
|
1.96B
est: 1.83B (+7.5%)
|
2.07B
est: 2.04B (+1.6%)
|
2.05B
est: 2.04B (+0.5%)
|
1.99B
est: 2.07B (-3.9%)
|
2.00B
est: 2.18B (-8.4%)
|
2.33B
2.32B – 2.35B
+6.8% YoY
|
2.46B
2.41B – 2.53B
+5.7% YoY
|
2.60B
2.59B – 2.61B
+5.6% YoY
|
2.76B
2.73B – 2.82B
+6.2% YoY
|
2.93B
2.90B – 2.99B
+6.2% YoY
|
| EPS |
2.78
est: 2.36 (+17.8%)
|
3.15
est: 3.30 (-4.4%)
|
0.77
est: 3.87 (-80.1%)
|
6.01
est: 4.63 (+29.9%)
|
1.27
est: 5.52 (-77.0%)
|
0.98
est: 6.38 (-84.6%)
|
1.46
est: 6.31 (-76.9%)
|
5.05
est: 8.91 (-43.4%)
|
5.82
est: 10.15 (-42.6%)
|
7.39
est: 7.81 (-5.4%)
|
7.57
est: 11.12 (-31.9%)
|
7.91
est: 11.89 (-33.5%)
|
12.80
12.63 – 12.88
+7.6% YoY
|
14.16
13.66 – 14.87
+10.6% YoY
|
15.76
13.16 – 18.74
+11.3% YoY
|
17.68
17.44 – 18.13
+12.2% YoY
|
19.62
19.35 – 20.12
+11.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-01 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
2.74B
OE per share TTM
16.00
Owner's Yield
9.23%
Maintenance CapEx ratio
7.34%
Maint CapEx / Avg PPE
6.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
394
Total invested
1.70B
Insider transactions (90d)
8
Beneficial owners (>5%)
29
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 16.9% (3) | 22.15M | 16.90% | — | — | — | — | IN | United States | 2014-02-14 | ↗ |
| 2 | 16.9% (4) | 22.15M | 16.90% | 21.13M | 1.03M | 21.13M | 1.03M | IN | United States | 2014-02-14 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 20.97M | 10.98% | — | 312.8K | 20.19M | 781.0K | IA | Pennsylvania | 2022-02-10 | ↗ |
| 4 | Canada Pension Plan Investment Board | 19.41M | 7.90% | 1.57M | 17.84M | 1.57M | 10.00 | CO | Canada | 2016-10-13 | ↗ |
| 5 | CPP Investment Board Private Holdings, Inc. | 17.84M | 7.30% | — | 17.84M | — | 10.00 | CO | Canada | 2016-10-13 | ↗ |
| 6 | (1) BlackRock, Inc. | 15.14M | 7.90% | 13.61M | — | 15.14M | — | HC | Delaware | 2022-02-07 | ↗ |
| 7 | 11.4% (3) | 14.33M | 11.40% | — | — | — | — | IN | United States | 2015-02-17 | ↗ |
| 8 | 11.4% (4) | 14.33M | 11.40% | 14.02M | 311.8K | 14.02M | 311.8K | IN | United States | 2015-02-17 | ↗ |
| 9 | GIC Private Limited | 9.13M | 5.01% | 6.20M | 2.93M | 6.20M | 2.93M | CO | Republic of Singapore | 2024-08-15 | ↗ |
| 10 | David Bonderman | 8.53M | 4.30% | — | 8.53M | — | — | IN | United States of America | 2019-03-12 | ↗ |
| 11 | James G. Coulter | 8.53M | 4.30% | — | 8.53M | — | — | IN | United States of America | 2019-03-12 | ↗ |
| 12 | TPG Advisors V, Inc. | 8.53M | 4.30% | — | 8.53M | — | — | CO | Delaware | 2019-03-12 | ↗ |
| 13 | TPG Advisors VI, Inc. | 8.53M | 4.30% | — | 8.53M | — | — | CO | Delaware | 2019-03-12 | ↗ |
| 14 | TPG Biotech Advisors, Inc. | 8.53M | 4.30% | — | 8.53M | — | — | CO | Delaware | 2019-03-12 | ↗ |
| 15 | TPG Group Holdings (SBS) Advisors, Inc. | 8.53M | 4.30% | — | 8.53M | — | — | CO | Delaware | 2019-03-12 | ↗ |
| 16 | Lone Pine Capital LLC | 7.71M | 3.80% | — | 7.71M | — | — | OO | Delaware | 2019-02-14 | ↗ |
| 17 | Stephen F. Mandel, Jr. | 7.71M | 3.80% | — | 7.71M | — | — | IN | United States of America | 2019-02-14 | ↗ |
| 18 | 04-2683227 | 6.74M | 5.23% | — | 2.01M | — | — | IA | Massachusetts | 2014-02-14 | ↗ |
| 19 | 13-3434400 | 6.73M | 11.00% | — | — | — | — | IA | Delaware | 2015-02-12 | ↗ |
| 20 | 2.1% (4) | 2.70M | 2.10% | 39.7K | 2.66M | 39.7K | 2.66M | IN | United States | 2014-02-14 | ↗ |
| 21 | 2.0% (2) | 2.66M | 2.00% | — | 2.66M | — | 2.66M | PN | United States | 2014-02-14 | ↗ |
| 22 | 1.4% (4) | 1.70M | 1.40% | 39.7K | 1.66M | 39.7K | 1.66M | IN | United States | 2015-02-17 | ↗ |
| 23 | 1.3% (2) | 1.66M | 1.30% | — | 1.66M | — | 1.66M | PN | United States | 2015-02-17 | ↗ |
| 24 | 0.5% (2) | 713.7K | 0.50% | — | 713.7K | — | 713.7K | PN | United States | 2014-02-14 | ↗ |
| 25 | Fullerton Management Pte Ltd | 639.2K | 0.50% | — | 639.2K | — | — | HC | Republic of Singapore | 2016-02-16 | ↗ |
| 26 | Temasek Holdings (Private) Limited | 639.2K | 0.50% | — | 639.2K | — | — | HC | Republic of Singapore | 2016-02-16 | ↗ |
| 27 | Temasek Life Sciences Private Limited | 639.2K | 0.50% | — | 639.2K | — | — | CO | Republic of Singapore | 2016-02-16 | ↗ |
| 28 | 0.1% (2) | 148.2K | 0.10% | — | 148.2K | — | 148.2K | PN | United States | 2015-02-17 | ↗ |
| 29 | 10 | — | 0.00% | — | — | — | — | PN | United States | 2015-02-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
394
-761 vs prev Q
New positions
30
Closed positions
772
Increased
185
Reduced
149
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 447.8K +447.8K (+100.0%) | 100.95B +100.9B (+100.0%) | 0.26% +0.261 pp | 0.15% +0.152 pp | USD225.41 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 19.65M +159.9K (+0.8%) | 4.43B +727.4M (+19.6%) | 11.43% +0.086 pp | 0.06% +0.009 pp | USD117.72 +91.5% | 33 qtrs — |
| 3 | BLACKROCK, INC. | 14.16M -628.5K (-4.2%) | 3.19B +382.9M (+13.6%) | 8.24% -0.371 pp | 0.05% +0.005 pp | USD234.12 -3.7% | 6 qtrs — |
| 4 | HARRIS ASSOCIATES L P | 11.32M -67.5K (-0.6%) | 2.55B +388.7M (+18.0%) | 6.59% -0.043 pp | 3.22% -0.243 pp | USD205.62 +9.6% | 11 qtrs — |
| 5 | STATE STREET CORP | 7.45M -102.0K (-1.4%) | 1.68B +244.8M (+17.1%) | 4.33% -0.062 pp | 0.06% +0.007 pp | USD125.14 +80.1% | 33 qtrs — |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 4.37M +24.5K (+0.6%) | 982.27M +159.4M (+19.4%) | 2.55% +0.013 pp | 0.06% +0.008 pp | USD149.54 +50.7% | 33 qtrs — |
| 7 | BOSTON PARTNERS | 4.09M +530.7K (+14.9%) | 923.28M +246.6M (+36.4%) | 2.38% +0.308 pp | 0.96% +0.261 pp | USD194.55 +15.9% | 2 qtrs — |
| 8 | JPMORGAN CHASE & CO | 3.80M +517.5K (+15.8%) | 856.47M +233.0M (+37.4%) | 2.21% +0.300 pp | 0.05% +0.016 pp | USD203.63 +10.7% | 33 qtrs — |
| 9 | FMR LLC | 3.48M -187.2K (-5.1%) | 784.03M +87.8M (+12.6%) | 2.05% -0.088 pp | 0.04% +0.004 pp | USD175.73 +28.3% | 33 qtrs — |
| 10 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 3.37M -62.6K (-1.8%) | 759.94M +107.7M (+16.5%) | 1.96% -0.038 pp | 1.14% +0.213 pp | USD159.11 +41.7% | 3 qtrs — |
| 11 | ALLIANCEBERNSTEIN L.P. | 3.30M -293.5K (-8.2%) | 744.76M +61.4M (+9.0%) | 1.92% -0.172 pp | 0.24% +0.020 pp | USD152.09 +48.2% | 33 qtrs — |
| 12 | MORGAN STANLEY | 2.58M +277.5K (+12.1%) | 581.11M +144.1M (+33.0%) | 1.50% +0.161 pp | 0.03% +0.008 pp | USD181.26 +24.4% | 33 qtrs — |
| 13 | INVESCO LTD. | 2.48M -293.0K (-10.6%) | 559.25M +32.4M (+6.1%) | 1.44% -0.171 pp | 0.09% +0.003 pp | USD179.52 +25.6% | 33 qtrs — |
| 14 | LONGVIEW PARTNERS (GUERNSEY) LTD | 2.22M -126.2K (-5.4%) | 500.51M +54.8M (+12.3%) | 1.29% -0.074 pp | 5.23% +0.568 pp | USD127.27 +77.1% | 24 qtrs — |
| 15 | NORGES BANK | 2.21M +2.2M (+100.0%) | 497.45M +497.4M (+100.0%) | 1.28% +1.284 pp | 0.05% +0.053 pp | USD225.41 +0.0% | 1 qtrs NEW |
| 16 | AQR CAPITAL MANAGEMENT LLC | 2.14M +361.5K (+20.3%) | 482.20M +160.6M (+49.9%) | 1.26% +0.224 pp | 0.25% +0.047 pp | USD184.60 +22.1% | 33 qtrs — |
| 17 | CANTILLON CAPITAL MANAGEMENT LLC | 1.94M +14.2K (+0.7%) | 437.55M +71.6M (+19.5%) | 1.13% +0.008 pp | 2.37% +0.351 pp | USD206.85 +9.0% | 20 qtrs — |
| 18 | ORBIS ALLAN GRAY LTD | 1.90M +933.6K (+96.5%) | 428.52M +244.8M (+133.2%) | 1.12% +0.555 pp | 1.80% +1.007 pp | USD206.47 +9.2% | 3 qtrs — |
| 19 | LAZARD ASSET MANAGEMENT LLC | 1.90M +57.9K (+3.1%) | 427.59M +78.3M (+22.4%) | 1.10% +0.033 pp | 0.72% +0.254 pp | USD142.69 +58.0% | 33 qtrs — |
| 20 | NORTHERN TRUST CORP | 1.73M -38.8K (-2.2%) | 390.95M +54.1M (+16.1%) | 1.02% -0.012 pp | 0.05% +0.007 pp | USD126.92 +77.6% | 33 qtrs — |
| 21 | CANADA PENSION PLAN INVESTMENT BOARD | 1.70M -2.4M (-58.6%) | 383.97M -397.7M (-50.9%) | 0.99% -1.405 pp | 0.26% -0.292 pp | USD153.25 +47.1% | 33 qtrs — |
| 22 | VICTORY CAPITAL MANAGEMENT INC | 1.68M +1.6M (+2,628.1%) | 377.67M +366.0M (+3,137.5%) | 0.99% +0.950 pp | 0.21% +0.206 pp | USD223.70 +0.8% | 33 qtrs — |
| 23 | GOLDMAN SACHS GROUP INC | 1.59M +284.0K (+21.7%) | 359.07M +110.4M (+44.4%) | 0.94% +0.174 pp | 0.04% +0.014 pp | USD214.62 +5.0% | 33 qtrs — |
| 24 | DIMENSIONAL FUND ADVISORS LP | 1.59M +169.0K (+11.9%) | 358.67M +88.7M (+32.8%) | 0.94% +0.108 pp | 0.08% +0.017 pp | USD171.70 +31.3% | 33 qtrs — |
| 25 | BANK OF AMERICA CORP /DE/ | 1.40M +217.1K (+18.4%) | 314.64M +90.7M (+40.5%) | 0.81% +0.126 pp | 0.02% +0.008 pp | USD196.79 +14.5% | 33 qtrs — |
| 26 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.38M +32.4K (+2.4%) | 310.68M +55.0M (+21.5%) | 0.81% +0.027 pp | 0.05% +0.008 pp | USD149.64 +50.6% | 33 qtrs — |
| 27 | CIBC PRIVATE WEALTH GROUP, LLC | 1.30M -19.4K (-1.5%) | 292.87M +42.4M (+16.9%) | 0.76% -0.012 pp | 0.50% +0.066 pp | USD207.24 +8.8% | 15 qtrs — |
| 28 | UBS ASSET MANAGEMENT AMERICAS INC | 1.27M +36.8K (+3.0%) | 285.92M +52.0M (+22.2%) | 0.74% +0.021 pp | 0.06% +0.010 pp | USD171.10 +31.7% | 33 qtrs — |
| 29 | RAYMOND JAMES FINANCIAL INC | 1.18M -49.8K (-4.0%) | 266.46M +32.7M (+14.0%) | 0.69% -0.022 pp | 0.08% +0.008 pp | USD196.03 +15.0% | 5 qtrs — |
| 30 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 1.13M +332.5K (+41.6%) | 255.18M +103.3M (+68.0%) | 0.67% +0.200 pp | 0.15% +0.063 pp | USD183.12 +23.1% | 33 qtrs — |
| 31 | AMUNDI | 1.08M -42.9K (-3.8%) | 242.37M +13.1M (+5.7%) | 0.63% -0.025 pp | 0.07% -0.008 pp | USD211.36 +6.6% | 19 qtrs — |
| 32 | LEGAL & GENERAL GROUP PLC | 1.07M -58.0K (-5.1%) | 242.15M +27.1M (+12.6%) | 0.62% -0.034 pp | 0.05% +0.006 pp | USD141.89 +58.9% | 33 qtrs — |
| 33 | FIL LTD | 1.06M +461.6K (+76.7%) | 239.66M +125.4M (+109.7%) | 0.63% +0.275 pp | 0.18% +0.090 pp | USD219.49 +2.7% | 30 qtrs — |
| 34 | AMERICAN CENTURY COMPANIES INC | 996.4K -248.0K (-19.9%) | 224.61M -11.8M (-5.0%) | 0.59% -0.138 pp | 0.11% -0.007 pp | USD183.62 +22.8% | 24 qtrs — |
| 35 | BANK OF NEW YORK MELLON CORP | 983.4K -40.5K (-4.0%) | 221.68M +27.2M (+14.0%) | 0.57% -0.024 pp | 0.04% +0.002 pp | USD129.24 +74.4% | 33 qtrs — |
| 36 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 962.1K +7.2K (+0.8%) | 216.88M +35.5M (+19.6%) | 0.57% +0.010 pp | 0.13% +0.013 pp | USD169.68 +32.8% | 6 qtrs — |
| 37 | JANE STREET GROUP, LLC | 932.3K -385.2K (-29.2%) | 210.15M -40.1M (-16.0%) | 0.55% -0.219 pp | 0.03% -0.006 pp | USD189.41 +19.0% | 6 qtrs — |
| 38 | WELLS FARGO & COMPANY/MN | 925.0K +250.0K (+37.0%) | 208.50M +80.3M (+62.6%) | 0.54% +0.145 pp | 0.04% +0.014 pp | USD220.60 +2.2% | 9 qtrs — |
| 39 | CAPITAL RESEARCH GLOBAL INVESTORS | 872.6K -28.7K (-3.2%) | 196.72M +25.6M (+15.0%) | 0.51% -0.017 pp | 0.04% +0.004 pp | USD173.20 +30.1% | 32 qtrs — |
| 40 | ALYESKA INVESTMENT GROUP, L.P. | 833.3K +289.0K (+53.1%) | 187.83M +84.5M (+81.7%) | 0.49% +0.173 pp | 0.53% +0.218 pp | USD181.11 +24.5% | 3 qtrs — |
| 41 | UBS GROUP AG | 814.1K -181.0K (-18.2%) | 183.50M -5.5M (-2.9%) | 0.47% -0.106 pp | 0.03% +0.000 pp | USD193.87 +16.3% | 33 qtrs — |
| 42 | KBC GROUP NV | 779.1K +315.9K (+68.2%) | 175.62M +87.6M (+99.6%) | 0.46% +0.188 pp | 0.40% +0.190 pp | USD223.80 +0.7% | 33 qtrs — |
| 43 | 1832 ASSET MANAGEMENT L.P. | 770.7K +769.1K (+47,067.0%) | 173.73M +173.4M (+55,875.1%) | 0.45% +0.452 pp | 0.13% +0.132 pp | USD225.37 +0.0% | 20 qtrs — |
| 44 | MILLENNIUM MANAGEMENT LLC | 736.9K +379.1K (+106.0%) | 166.10M +98.1M (+144.4%) | 0.43% +0.220 pp | 0.07% +0.041 pp | USD214.57 +5.1% | 33 qtrs — |
| 45 | NORDEA INVESTMENT MANAGEMENT AB | 713.3K -1.6M (-69.2%) | 161.51M -259.7M (-61.7%) | 0.42% -0.928 pp | 0.14% -0.230 pp | USD177.97 +26.7% | 33 qtrs — |
| 46 | PRICE T ROWE ASSOCIATES INC /MD/ | 696.6K +1.6K (+0.2%) | 157.02M +25.0M (+19.0%) | 0.41% +0.001 pp | 0.02% +0.003 pp | USD184.07 +22.5% | 33 qtrs — |
| 47 | DEUTSCHE BANK AG\ | 691.0K -117.1K (-14.5%) | 155.76M +2.3M (+1.5%) | 0.40% -0.068 pp | 0.05% -0.001 pp | USD202.20 +11.5% | 33 qtrs — |
| 48 | VIKING GLOBAL INVESTORS LP | 619.2K +619.2K (+100.0%) | 139.58M +139.6M (+100.0%) | 0.36% +0.360 pp | 0.37% +0.371 pp | USD225.41 +0.0% | 1 qtrs NEW |
| 49 | CAPITAL WORLD INVESTORS | 594.7K +3.5K (+0.6%) | 134.06M +21.8M (+19.4%) | 0.35% +0.002 pp | 0.02% +0.003 pp | USD208.47 +8.1% | 7 qtrs — |
| 50 | ENVESTNET ASSET MANAGEMENT INC | 591.8K -56.2K (-8.7%) | 133.40M +10.3M (+8.4%) | 0.34% -0.033 pp | 0.04% +0.004 pp | USD183.18 +23.1% | 33 qtrs — |
| 51 | EARNEST PARTNERS LLC | 553.9K -11.5K (-2.0%) | 124.86M +17.5M (+16.3%) | 0.33% -0.003 pp | 0.54% +0.069 pp | USD212.17 +6.2% | 6 qtrs — |
| 52 | CADIAN CAPITAL MANAGEMENT, LP | 549.7K -253.4K (-31.6%) | 123.90M -28.6M (-18.8%) | 0.32% -0.144 pp | 8.95% -0.115 pp | USD186.01 +21.2% | 5 qtrs — |
| 53 | CITADEL ADVISORS LLC | 547.9K +469.1K (+594.6%) | 123.51M +108.5M (+724.3%) | 0.32% +0.273 pp | 0.02% +0.016 pp | USD220.45 +2.2% | 33 qtrs — |
| 54 | CITIGROUP INC | 540.8K -374.3K (-40.9%) | 121.91M -51.9M (-29.9%) | 0.32% -0.215 pp | 0.05% -0.024 pp | USD185.45 +21.5% | 33 qtrs — |
| 55 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 523.7K +15.8K (+3.1%) | 118.21M +21.7M (+22.5%) | 0.31% +0.012 pp | 0.10% +0.018 pp | USD194.03 +16.2% | 33 qtrs — |
| 56 | ROYAL BANK OF CANADA | 516.9K +167.3K (+47.8%) | 116.52M +50.1M (+75.5%) | 0.30% +0.097 pp | 0.02% +0.008 pp | USD199.48 +13.0% | 33 qtrs — |
| 57 | NUVEEN, LLC | 513.1K +43.4K (+9.2%) | 115.67M +26.4M (+29.6%) | 0.30% +0.025 pp | 0.03% +0.007 pp | USD180.80 +24.7% | 4 qtrs — |
| 58 | FRANKLIN RESOURCES INC | 505.2K +86.0K (+20.5%) | 113.89M +34.3M (+43.0%) | 0.29% +0.050 pp | 0.03% +0.008 pp | USD155.40 +45.1% | 33 qtrs — |
| 59 | BNP PARIBAS ARBITRAGE, SNC | 500.0K +198.2K (+65.7%) | 112.70M +55.4M (+96.6%) | 0.29% +0.115 pp | 0.05% +0.021 pp | USD213.66 +5.5% | 33 qtrs — |
| 60 | AMERIPRISE FINANCIAL INC | 492.2K -129.2K (-20.8%) | 110.94M -7.1M (-6.0%) | 0.29% -0.072 pp | 0.03% -0.002 pp | USD212.25 +6.2% | 33 qtrs — |
| 61 | SWISS NATIONAL BANK | 465.9K -32.8K (-6.6%) | 105.01M +10.3M (+10.9%) | 0.27% -0.019 pp | 0.06% +0.008 pp | USD133.09 +69.4% | 33 qtrs — |
| 62 | VONTOBEL HOLDING LTD. | 458.1K -92.4K (-16.8%) | 103.25M -1.3M (-1.2%) | 0.27% -0.054 pp | 0.33% +0.010 pp | USD191.36 +17.8% | 21 qtrs — |
| 63 | CORNERSTONE INVESTMENT PARTNERS, LLC | 453.9K +109.7K (+31.9%) | 102.30M +36.9M (+56.5%) | 0.27% +0.066 pp | 3.97% +1.235 pp | USD178.39 +26.4% | 3 qtrs — |
| 64 | CANDRIAM S.C.A. | 447.3K +174.6K (+64.0%) | 100.83M +49.0M (+94.6%) | 0.26% +0.104 pp | 0.50% +0.231 pp | USD213.19 +5.7% | 33 qtrs — |
| 65 | PRIMECAP MANAGEMENT CO/CA/ | 432.1K -37.1K (-7.9%) | 97.39M +8.3M (+9.3%) | 0.25% -0.022 pp | 0.07% +0.006 pp | USD167.80 +34.3% | 24 qtrs — |
| 66 | LORD, ABBETT & CO. LLC | 379.5K +379.5K (+100.0%) | 85.55M +85.6M (+100.0%) | 0.22% +0.221 pp | 0.26% +0.263 pp | USD225.41 +0.0% | 1 qtrs NEW |
| 67 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 353.1K +11.3K (+3.3%) | 79.57M +14.6M (+22.6%) | 0.21% +0.009 pp | 0.05% +0.007 pp | USD198.69 +13.4% | 33 qtrs — |
| 68 | HSBC HOLDINGS PLC | 338.3K -26.1K (-7.2%) | 76.30M +7.2M (+10.4%) | 0.20% -0.013 pp | 0.04% +0.001 pp | USD181.06 +24.5% | 33 qtrs — |
| 69 | EDMOND DE ROTHSCHILD HOLDING S.A. | 332.4K +237.8K (+251.2%) | 74.93M +57.0M (+316.7%) | 0.20% +0.140 pp | 1.06% +0.786 pp | USD215.73 +4.5% | 19 qtrs — |
| 70 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 330.6K -372.0 (-0.1%) | 74.53M +11.7M (+18.5%) | 0.19% +0.002 pp | 0.04% +0.005 pp | USD133.58 +68.7% | 33 qtrs — |
| 71 | VULCAN VALUE PARTNERS, LLC | 323.2K -357.7K (-52.5%) | 72.85M -57.1M (-43.9%) | 0.19% -0.208 pp | 1.31% -1.041 pp | USD158.17 +42.5% | 3 qtrs — |
| 72 | ALLIANZ ASSET MANAGEMENT GMBH | 322.7K +48.8K (+17.8%) | 72.73M +20.7M (+39.8%) | 0.19% +0.028 pp | 0.07% +0.016 pp | USD191.10 +18.0% | 33 qtrs — |
| 73 | RHUMBLINE ADVISERS | 317.3K -123.7K (-28.1%) | 71.52M -12.2M (-14.6%) | 0.18% -0.072 pp | 0.06% -0.010 pp | USD145.46 +55.0% | 33 qtrs — |
| 74 | EULAV ASSET MANAGEMENT | 309.0K +3.0 (+0.0%) | 69.65M +11.0M (+18.7%) | 0.18% 0.000 pp | 1.86% +0.494 pp | USD206.78 +9.0% | 30 qtrs — |
| 75 | BALYASNY ASSET MANAGEMENT L.P. | 289.4K +289.4K (+100.0%) | 65.24M +65.2M (+100.0%) | 0.17% +0.170 pp | 0.08% +0.083 pp | USD225.41 +0.0% | 1 qtrs NEW |
| 76 | APPALOOSA LP | 280.0K -5.0K (-1.8%) | 63.11M +9.0M (+16.6%) | 0.16% -0.003 pp | 0.91% +0.178 pp | USD157.59 +43.0% | 3 qtrs — |
| 77 | NATIONAL PENSION SERVICE | 275.1K -12.0K (-4.2%) | 62.01M +7.5M (+13.7%) | 0.16% -0.007 pp | 0.05% +0.004 pp | USD167.51 +34.6% | 33 qtrs — |
| 78 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 269.1K -15.5K (-5.5%) | 60.66M +6.6M (+12.2%) | 0.16% -0.007 pp | 0.06% +0.005 pp | USD118.32 +90.5% | 33 qtrs — |
| 79 | FIRST MANHATTAN CO. LLC. | 268.9K +13.7K (+5.4%) | 60.61M +12.1M (+25.1%) | 0.16% +0.008 pp | 0.16% +0.031 pp | USD168.77 +33.6% | 33 qtrs — |
| 80 | BARCLAYS PLC | 262.0K -15.6K (-5.6%) | 59.05M -6.7M (-10.2%) | 0.15% -0.009 pp | 0.01% -0.003 pp | USD201.83 +11.7% | 33 qtrs — |
| 81 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 259.8K +8.1K (+3.2%) | 58.56M +10.7M (+22.5%) | 0.15% +0.005 pp | 0.04% +0.005 pp | USD203.81 +10.6% | 33 qtrs — |
| 82 | HANDELSBANKEN FONDER AB | 258.5K +126.6K (+95.9%) | 58.28M +33.2M (+132.5%) | 0.15% +0.074 pp | 0.18% +0.096 pp | USD221.52 +1.8% | 23 qtrs — |
| 83 | CLARKSTON CAPITAL PARTNERS, LLC | 252.5K -9.5K (-3.6%) | 56.92M +7.2M (+14.4%) | 0.15% -0.004 pp | 1.32% +0.246 pp | USD163.64 +37.7% | 9 qtrs — |
| 84 | KEYSTONE INVESTORS PTE LTD | 245.9K +99.7K (+68.2%) | 55.43M +27.7M (+99.6%) | 0.14% +0.058 pp | 4.98% +1.769 pp | USD191.92 +17.4% | 3 qtrs — |
| 85 | PGGM INVESTMENTS | 243.5K +44.8K (+22.5%) | 54.88M +17.1M (+45.4%) | 0.14% +0.026 pp | 0.87% +0.258 pp | USD178.62 +26.2% | 14 qtrs — |
| 86 | ARTEMIS INVESTMENT MANAGEMENT LLP | 234.3K +234.3K (+100.0%) | 52.81M +52.8M (+100.0%) | 0.14% +0.138 pp | 0.64% +0.638 pp | USD225.41 +0.0% | 1 qtrs NEW |
| 87 | CIBC ASSET MANAGEMENT INC | 232.7K -4.7K (-2.0%) | 52.45M +7.4M (+16.3%) | 0.14% -0.003 pp | 0.13% -0.004 pp | USD181.79 +24.0% | 33 qtrs — |
| 88 | DEKABANK DEUTSCHE GIROZENTRALE | 198.6K +— (+0.0%) | 51.18M +15.1M (+41.8%) | 0.12% 0.000 pp | 0.09% +0.028 pp | USD205.20 +9.8% | 28 qtrs — |
| 89 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 226.6K +27.5K (+13.8%) | 51.09M +13.3M (+35.1%) | 0.13% +0.017 pp | 0.02% +0.005 pp | USD205.61 +9.6% | 13 qtrs — |
| 90 | ASSENAGON ASSET MANAGEMENT S.A. | 223.7K -21.4K (-8.7%) | 50.43M +3.9M (+8.3%) | 0.13% -0.011 pp | 0.07% +0.006 pp | USD203.13 +11.0% | 29 qtrs — |
| 91 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 216.7K +17.8K (+8.9%) | 48.84M +11.1M (+29.3%) | 0.13% +0.012 pp | 0.20% +0.044 pp | USD178.15 +26.5% | 30 qtrs — |
| 92 | BANK OF MONTREAL /CAN/ | 214.8K +27.8K (+14.9%) | 48.42M +12.9M (+36.3%) | 0.13% +0.016 pp | 0.02% +0.003 pp | USD211.39 +6.6% | 33 qtrs — |
| 93 | VINVA INVESTMENT MANAGEMENT LTD | 211.4K +38.0K (+21.9%) | 48.14M +16.6M (+52.9%) | 0.12% +0.022 pp | 0.60% -0.016 pp | USD181.85 +24.0% | 12 qtrs — |
| 94 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 207.9K -90.4K (-30.3%) | 46.86M -9.8M (-17.3%) | 0.12% -0.052 pp | 0.08% -0.026 pp | USD212.78 +5.9% | 32 qtrs — |
| 95 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 206.9K +206.9K (+100.0%) | 46.64M +46.6M (+100.0%) | 0.12% +0.122 pp | 0.05% +0.054 pp | USD225.41 +0.0% | 33 qtrs — |
| 96 | THOMPSON SIEGEL & WALMSLEY LLC | 203.5K -75.5K (-27.1%) | 45.87M -7.1M (-13.4%) | 0.12% -0.044 pp | 0.77% -0.086 pp | USD181.60 +24.1% | 12 qtrs — |
| 97 | GLENVIEW CAPITAL MANAGEMENT, LLC | 199.7K +25.0K (+14.3%) | 45.02M +11.8M (+35.7%) | 0.12% +0.015 pp | 0.92% +0.177 pp | USD178.18 +26.5% | 3 qtrs — |
| 98 | GLENMEDE TRUST CO NA | 199.7K +199.7K (+100.0%) | 45.00M +45.0M (+100.0%) | 0.12% +0.116 pp | 0.21% +0.213 pp | USD225.41 +0.0% | 1 qtrs NEW |
| 99 | COUNTRY TRUST BANK | 197.5K +4.2K (+2.1%) | 44.53M +7.8M (+21.2%) | 0.12% +0.004 pp | 0.81% +0.002 pp | USD220.71 +2.1% | 18 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.92
Bullish
Ratio by volume
3.00
Bullish
Buys
23
Sells
12
Shares acquired
316.0K
Shares disposed
50.4K
Cash buys
—
Cash sales
—
Net activity
+265,555
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 1,571 | 0.00 | — | 6,465 | D | ↗ |
| 2026-04-23 | Stamps Sheila A | Director | A-Award | A | Deferred Shares | 1,571 | 0.00 | — | 4,210 | D | ↗ |
| 2026-04-23 | LEONARD JOHN M | Director | A-Award | A | Common Stock | 1,571 | 0.00 | — | 16,946 | D | ↗ |
| 2026-04-23 | Kaelin William G Jr | Director | A-Award | A | Deferred Shares | 1,571 | 0.00 | — | 1,571 | D | ↗ |
| 2026-04-23 | GOGGINS COLLEEN A | Director | A-Award | A | Common Stock | 1,571 | 0.00 | — | 14,453 | D | ↗ |
| 2026-04-23 | Fasano Jim | Director | A-Award | A | Deferred Shares | 1,571 | 0.00 | — | 5,845 | D | ↗ |
| 2026-04-23 | DANHAKL JOHN G | Director | A-Award | A | Common Stock | 1,571 | 0.00 | — | 30,612 | I | ↗ |
| 2026-04-23 | Burt Carol | Director | A-Award | A | Common Stock | 1,571 | 0.00 | — | 7,533 | I | ↗ |
| 2026-02-13 | Haas Bernd | Officer | F-InKind | D | Common Stock | 20 | 166.94 | 3.3K | 24,394 | D | ↗ |
| 2026-02-13 | Fedock Michael J. | Officer | F-InKind | D | Common Stock | 123 | 166.94 | 20.5K | 9,472 | D | ↗ |
| 2026-02-09 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 159 | 0.00 | — | 4,894 | D | ↗ |
| 2026-02-09 | Sherbet Eric | Officer | A-Award | A | Stock Appreciation Right | 12,112 | 192.67 | 2.33M | 12,112 | D | ↗ |
| 2026-02-09 | STAUB W RICHARD | Officer | A-Award | A | Stock Appreciation Right | 26,088 | 192.67 | 5.03M | 26,088 | D | ↗ |
| 2026-02-09 | Patel Bhavik | Officer | A-Award | A | Stock Appreciation Right | 11,180 | 192.67 | 2.15M | 11,180 | D | ↗ |
| 2026-02-09 | Haas Bernd | Officer | A-Award | A | Stock Appreciation Right | 11,180 | 192.67 | 2.15M | 11,180 | D | ↗ |
| 2026-02-09 | Grenfell Alistair | Officer | A-Award | A | Stock Appreciation Right | 26,088 | 192.67 | 5.03M | 26,088 | D | ↗ |
| 2026-02-09 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 198 | 0.00 | — | 4,900 | D | ↗ |
| 2026-02-09 | Fedock Michael J. | Officer | A-Award | A | Stock Appreciation Right | 18,634 | 192.67 | 3.59M | 18,634 | D | ↗ |
| 2026-02-09 | Fasano Jim | Director | A-Award | A | Deferred Shares | 211 | 0.00 | — | 4,274 | D | ↗ |
| 2026-02-09 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 172 | 0.00 | — | 2,944 | D | ↗ |
| 2026-02-09 | Cherofsky Keriann | Officer | A-Award | A | Stock Appreciation Right | 2,795 | 192.67 | 538.5K | 2,795 | D | ↗ |
| 2026-02-09 | Berkshire James G. | Officer | A-Award | A | Stock Appreciation Right | 11,180 | 192.67 | 2.15M | 11,180 | D | ↗ |
| 2026-02-09 | BOUSBIB ARI | Director / Officer | A-Award | A | Stock Appreciation Right | 78,264 | 192.67 | 15.08M | 78,264 | D | ↗ |
| 2026-02-08 | Sherbet Eric | Officer | F-InKind | D | Common Stock | 1,915 | 187.49 | 359.0K | 25,999 | D | ↗ |
| 2026-02-08 | STAUB W RICHARD | Officer | F-InKind | D | Common Stock | 806 | 187.49 | 151.1K | 18,812 | D | ↗ |
| 2026-02-08 | Patel Bhavik | Officer | A-Award | A | Common Stock | 4,083 | 0.00 | — | 5,123 | D | ↗ |
| 2026-02-08 | Haas Bernd | Officer | A-Award | A | Common Stock | 8,265 | 0.00 | — | 24,854 | D | ↗ |
| 2026-02-08 | Grenfell Alistair | Officer | F-InKind | D | Common Stock | 5,545 | 187.49 | 1.04M | 24,124 | D | ↗ |
| 2026-02-08 | Fedock Michael J. | Officer | F-InKind | D | Common Stock | 2,420 | 187.49 | 453.7K | 9,595 | D | ↗ |
| 2026-02-08 | Cherofsky Keriann | Officer | A-Award | A | Common Stock | 1,087 | 0.00 | — | 3,962 | D | ↗ |
| 2026-02-08 | Bruehlman Ronald E | Officer | A-Award | A | Common Stock | 16,335 | 0.00 | — | 50,904 | D | ↗ |
| 2026-02-08 | Berkshire James G. | Officer | A-Award | A | Common Stock | 2,722 | 0.00 | — | 9,457 | D | ↗ |
| 2026-02-08 | BOUSBIB ARI | Director / Officer | A-Award | A | Common Stock | 57,177 | 0.00 | — | 864,340 | D | ↗ |
| 2026-02-07 | Fedock Michael J. | Officer | F-InKind | D | Common Stock | 111 | 187.49 | 20.8K | 5,280 | D | ↗ |
| 2026-01-28 | Fedock Michael J. | Officer | F-InKind | D | Common Stock | 381 | 239.76 | 91.3K | 5,391 | D | ↗ |
| 2025-12-31 | Haas Bernd | Officer | — | — | Stock Appreciation Right | 8,778 | 203.43 | 1.79M | 0 | D | ↗ |
| 2025-12-31 | Grenfell Alistair | Officer | — | — | Stock Appreciation Right | 10,300 | 232.11 | 2.39M | 0 | D | ↗ |
| 2025-12-31 | Fedock Michael J. | Officer | — | — | Stock Appreciation Right | 3,453 | 214.34 | 740.1K | 0 | D | ↗ |
| 2025-12-31 | Berkshire James G. | Officer | — | — | Stock Appreciation Right | 8,778 | 203.43 | 1.79M | 0 | D | ↗ |
| 2025-12-18 | BOUSBIB ARI | Director / Officer | M-Exempt | D | Stock Appreciation Right | 50,000 | 59.90 | 3.00M | 0 | D | ↗ |
| 2025-11-05 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 146 | 0.00 | — | 4,735 | D | ↗ |
| 2025-11-05 | Kaelin William G Jr | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-11-05 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 181 | 0.00 | — | 4,702 | D | ↗ |
| 2025-11-05 | Fasano Jim | Director | A-Award | A | Deferred Shares | 193 | 0.00 | — | 4,063 | D | ↗ |
| 2025-11-05 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 158 | 0.00 | — | 2,772 | D | ↗ |
| 2025-10-29 | Sherbet Eric | Officer | M-Exempt | D | Stock Appreciation Right | 10,000 | 131.82 | 1.32M | 8,436 | D | ↗ |
| 2025-10-29 | BOUSBIB ARI | Director / Officer | S-Sale | D | Common Stock | 800 | 217.58 | 174.1K | 883,955 | D | ↗ |
| 2025-07-28 | Patel Bhavik | Officer | F-InKind | D | Common Stock | 84 | 197.76 | 16.6K | 1,040 | D | ↗ |
| 2025-07-28 | Cherofsky Keriann | Officer | F-InKind | D | Common Stock | 35 | 197.76 | 6.9K | 2,875 | D | ↗ |
| 2025-07-24 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 137 | 0.00 | — | 4,589 | D | ↗ |
| 2025-07-24 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 174 | 0.00 | — | 4,521 | D | ↗ |
| 2025-07-24 | Fasano Jim | Director | A-Award | A | Deferred Shares | 187 | 0.00 | — | 3,870 | D | ↗ |
| 2025-07-24 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 149 | 0.00 | — | 2,614 | D | ↗ |
| 2025-07-23 | Sherbet Eric | Officer | M-Exempt | D | Stock Appreciation Right | 11,870 | 97.20 | 1.15M | 0 | D | ↗ |
| 2025-07-23 | Cherofsky Keriann | Officer | S-Sale | D | Common Stock | 549 | 191.53 | 105.1K | 2,910 | D | ↗ |
| 2025-05-07 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 179 | 0.00 | — | 4,452 | D | ↗ |
| 2025-05-07 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 229 | 0.00 | — | 4,347 | D | ↗ |
| 2025-05-07 | Fasano Jim | Director | A-Award | A | Deferred Shares | 244 | 0.00 | — | 3,683 | D | ↗ |
| 2025-05-07 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 196 | 0.00 | — | 2,465 | D | ↗ |
| 2025-04-24 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 1,592 | 0.00 | — | 4,273 | D | ↗ |
| 2025-04-24 | Stamps Sheila A | Director | A-Award | A | Deferred Shares | 1,592 | 0.00 | — | 2,639 | D | ↗ |
| 2025-04-24 | LEONARD JOHN M | Director | A-Award | A | Common Stock | 1,592 | 0.00 | — | 15,375 | D | ↗ |
| 2025-04-24 | GOGGINS COLLEEN A | Director | A-Award | A | Common Stock | 1,592 | 0.00 | — | 12,882 | D | ↗ |
| 2025-04-24 | Fasano Jim | Director | A-Award | A | Deferred Shares | 1,592 | 0.00 | — | 3,439 | D | ↗ |
| 2025-04-24 | DANHAKL JOHN G | Director | A-Award | A | Common Stock | 1,592 | 0.00 | — | 29,041 | I | ↗ |
| 2025-04-24 | Burt Carol | Director | A-Award | A | Deferred Shares | 1,592 | 0.00 | — | 2,639 | D | ↗ |
| 2025-02-10 | Sherbet Eric | Officer | F-InKind | D | Common Stock | 179 | 206.97 | 37.0K | 21,108 | D | ↗ |
| 2025-02-10 | STAUB W RICHARD | Officer | F-InKind | D | Common Stock | 141 | 206.97 | 29.2K | 16,896 | D | ↗ |
| 2025-02-10 | Patel Bhavik | Officer | F-InKind | D | Common Stock | 108 | 206.97 | 22.4K | 1,124 | D | ↗ |
| 2025-02-10 | Haas Bernd | Officer | — | — | Stock Appreciation Right | 2,002 | 250.43 | 501.4K | 0 | D | ↗ |
| 2025-02-10 | Grenfell Alistair | Officer | — | — | Stock Appreciation Right | 8,193 | 250.43 | 2.05M | 0 | D | ↗ |
| 2025-02-10 | Fedock Michael J. | Officer | — | — | Stock Appreciation Right | 2,184 | 250.43 | 546.9K | 0 | D | ↗ |
| 2025-02-10 | Cherofsky Keriann | Officer | F-InKind | D | Common Stock | 16 | 206.97 | 3.3K | 3,459 | D | ↗ |
| 2025-02-10 | Bruehlman Ronald E | Officer | F-InKind | D | Common Stock | 907 | 206.97 | 187.7K | 34,569 | D | ↗ |
| 2025-02-10 | Berkshire James G. | Officer | — | — | Stock Appreciation Right | 3,641 | 250.43 | 911.8K | 0 | D | ↗ |
| 2025-02-10 | BOUSBIB ARI | Director / Officer | M-Exempt | A | Common Stock | 40,000 | 65.16 | 2.61M | 837,083 | D | ↗ |
| 2025-02-05 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 134 | 0.00 | — | 2,681 | D | ↗ |
| 2025-02-05 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 170 | 0.00 | — | 4,118 | D | ↗ |
| 2025-02-05 | Fasano Jim | Director | A-Award | A | Deferred Shares | 171 | 0.00 | — | 1,847 | D | ↗ |
| 2025-02-05 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 146 | 0.00 | — | 2,269 | D | ↗ |
| 2025-02-05 | CONNAUGHTON JOHN | Director | A-Award | A | Deferred Shares | 133 | 0.00 | — | 133 | D | ↗ |
| 2025-01-28 | Sherbet Eric | Officer | A-Award | A | Common Stock | 2,356 | 0.00 | — | 21,892 | D | ↗ |
| 2025-01-28 | STAUB W RICHARD | Officer | F-InKind | D | Common Stock | 479 | 203.43 | 97.4K | 17,037 | D | ↗ |
| 2025-01-28 | Patel Bhavik | Officer | A-Award | A | Common Stock | 1,299 | 0.00 | — | 1,844 | D | ↗ |
| 2025-01-28 | Cherofsky Keriann | Officer | A-Award | A | Common Stock | 441 | 0.00 | — | 1,194 | D | ↗ |
| 2025-01-28 | Bruehlman Ronald E | Officer | A-Award | A | Common Stock | 6,286 | 0.00 | — | 37,677 | D | ↗ |
| 2025-01-28 | BOUSBIB ARI | Director / Officer | A-Award | A | Common Stock | 22,000 | 0.00 | — | 807,583 | D | ↗ |
| 2024-12-03 | DANHAKL JOHN G | Director | P-Purchase | A | Common Stock | 1,275 | 200.58 | 255.7K | 1,275 | I | ↗ |
| 2024-11-06 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 124 | 0.00 | — | 2,547 | D | ↗ |
| 2024-11-06 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 158 | 0.00 | — | 3,948 | D | ↗ |
| 2024-11-06 | Fasano Jim | Director | A-Award | A | Deferred Shares | 158 | 0.00 | — | 1,676 | D | ↗ |
| 2024-11-06 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 135 | 0.00 | — | 2,123 | D | ↗ |
| 2024-08-27 | Sherbet Eric | Officer | S-Sale | D | Common Stock | 1,300 | 246.33 | 320.2K | 19,536 | — | ↗ |
| 2024-07-28 | Patel Bhavik | Officer | F-InKind | D | Common Stock | 83 | 239.67 | 19.9K | 545 | — | ↗ |
| 2024-07-28 | Cherofsky Keriann | Officer | F-InKind | D | Common Stock | 35 | 239.67 | 8.4K | 753 | — | ↗ |
| 2024-07-18 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 123 | 0.00 | — | 2,423 | — | ↗ |
| 2024-07-18 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 156 | 0.00 | — | 3,790 | — | ↗ |
| 2024-07-18 | Fasano Jim | Director | A-Award | A | Deferred Shares | 155 | 0.00 | — | 1,518 | — | ↗ |
| 2024-07-18 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 134 | 0.00 | — | 1,988 | — | ↗ |
| 2024-05-07 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 1,167 | 0.00 | — | 2,300 | — | ↗ |
| 2024-05-07 | Stamps Sheila A | Director | A-Award | A | Deferred Shares | 1,047 | 0.00 | — | 1,047 | — | ↗ |
| 2024-05-07 | Patel Bhavik | Officer | — | D | Stock Appreciation Right | 2,549 | 250.43 | 638.3K | 0 | — | ↗ |
| 2024-05-07 | LEONARD JOHN M | Director | A-Award | A | Common Stock | 1,047 | 0.00 | — | 13,783 | — | ↗ |
| 2024-05-07 | GOGGINS COLLEEN A | Director | A-Award | A | Common Stock | 1,047 | 0.00 | — | 11,290 | — | ↗ |
| 2024-05-07 | Fasano Jim | Director | A-Award | A | Deferred Shares | 1,200 | 0.00 | — | 1,363 | — | ↗ |
| 2024-05-07 | DANHAKL JOHN G | Director | A-Award | A | Common Stock | 1,047 | 0.00 | — | 27,449 | — | ↗ |
| 2024-05-07 | CONNAUGHTON JOHN | Director | A-Award | A | Common Stock | 1,047 | 0.00 | — | 1,047 | — | ↗ |
| 2024-05-07 | Burt Carol | Director | A-Award | A | Deferred Shares | 1,047 | 0.00 | — | 1,047 | — | ↗ |
| 2024-04-15 | Berkshire James G. | Officer | — | — | Stock Appreciation Right | 1,131 | 214.13 | 242.2K | 0 | D | ↗ |
| 2024-03-01 | BOUSBIB ARI | Director / Officer | M-Exempt | D | Stock Appreciation Right | 42,847 | 65.16 | 2.79M | 40,000 | — | ↗ |
| 2024-02-29 | STAUB W RICHARD | Officer | S-Sale | D | Common Stock | 3,062 | 248.33 | 760.4K | 18,013 | — | ↗ |
| 2024-02-28 | Knightly Kevin C | Officer | M-Exempt | A | Common Stock | 7,131 | 95.23 | 679.1K | 13,858 | — | ↗ |
| 2024-02-16 | Sherbet Eric | Officer | S-Sale | D | Common Stock | 1,000 | 241.50 | 241.5K | 20,836 | — | ↗ |
| 2024-02-16 | Knightly Kevin C | Officer | S-Sale | D | Common Stock | 3,341 | 240.72 | 804.2K | 14,720 | — | ↗ |
| 2024-02-10 | Sherbet Eric | Officer | F-InKind | D | Common Stock | 289 | 218.20 | 63.1K | 21,836 | — | ↗ |
| 2024-02-10 | STAUB W RICHARD | Officer | F-InKind | D | Common Stock | 215 | 218.20 | 46.9K | 30,045 | — | ↗ |
| 2024-02-10 | Knightly Kevin C | Officer | F-InKind | D | Common Stock | 303 | 218.20 | 66.1K | 5,912 | — | ↗ |
| 2024-02-10 | Cherofsky Keriann | Officer | F-InKind | D | Common Stock | 15 | 218.20 | 3.3K | 788 | — | ↗ |
| 2024-02-10 | Bruehlman Ronald E | Officer | F-InKind | D | Common Stock | 907 | 218.20 | 197.9K | 31,391 | — | ↗ |
| 2024-02-10 | BOUSBIB ARI | Director / Officer | F-InKind | D | Common Stock | 3,335 | 218.20 | 727.7K | 785,583 | — | ↗ |
| 2024-02-09 | Sherbet Eric | Officer | F-InKind | D | Common Stock | 281 | 218.20 | 61.3K | 22,125 | — | ↗ |
| 2024-02-09 | STAUB W RICHARD | Officer | F-InKind | D | Common Stock | 353 | 218.20 | 77.0K | 30,260 | — | ↗ |
| 2024-02-09 | Knightly Kevin C | Officer | F-InKind | D | Common Stock | 311 | 218.20 | 67.9K | 6,215 | — | ↗ |
| 2024-02-09 | Haas Bernd | Officer | — | — | Stock Appreciation Right | 1,869 | 183.82 | 343.6K | 0 | D | ↗ |
| 2024-02-09 | Fedock Michael J. | Officer | — | — | Stock Appreciation Right | 534 | 183.82 | 98.2K | 0 | D | ↗ |
| 2024-02-09 | Cherofsky Keriann | Officer | F-InKind | D | Common Stock | 61 | 218.20 | 13.3K | 803 | — | ↗ |
| 2024-02-09 | Bruehlman Ronald E | Officer | F-InKind | D | Common Stock | 1,033 | 218.20 | 225.4K | 32,298 | — | ↗ |
| 2024-02-09 | Berkshire James G. | Officer | — | — | Stock Appreciation Right | 2,670 | 183.82 | 490.8K | 0 | D | ↗ |
| 2024-02-09 | BOUSBIB ARI | Director / Officer | F-InKind | D | Common Stock | 3,909 | 218.20 | 852.9K | 788,918 | — | ↗ |
| 2024-02-07 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 128 | 0.00 | — | 1,133 | — | ↗ |
| 2024-02-07 | Sherbet Eric | Officer | A-Award | A | Stock Appreciation Right | 9,496 | 214.34 | 2.04M | 9,496 | — | ↗ |
| 2024-02-07 | STAUB W RICHARD | Officer | A-Award | A | Stock Appreciation Right | 13,812 | 214.34 | 2.96M | 13,812 | — | ↗ |
| 2024-02-07 | Knightly Kevin C | Officer | A-Award | A | Stock Appreciation Right | 6,906 | 214.34 | 1.48M | 6,906 | — | ↗ |
| 2024-02-07 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 163 | 0.00 | — | 3,481 | — | ↗ |
| 2024-02-07 | Fasano Jim | Director | A-Award | A | Deferred Shares | 163 | 0.00 | — | 163 | — | ↗ |
| 2024-02-07 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 140 | 0.00 | — | 1,723 | — | ↗ |
| 2024-02-07 | Cherofsky Keriann | Officer | A-Award | A | Stock Appreciation Right | 1,726 | 214.34 | 370.0K | 1,726 | — | ↗ |
| 2024-02-07 | Bruehlman Ronald E | Officer | A-Award | A | Stock Appreciation Right | 20,719 | 214.34 | 4.44M | 20,719 | — | ↗ |
| 2024-02-07 | BOUSBIB ARI | Director / Officer | A-Award | A | Stock Appreciation Right | 72,517 | 214.34 | 15.54M | 72,517 | — | ↗ |
| 2024-02-06 | Sherbet Eric | Officer | A-Award | A | Common Stock | 7,725 | 0.00 | — | 24,778 | — | ↗ |
| 2024-02-06 | STAUB W RICHARD | Officer | A-Award | A | Common Stock | 8,690 | 0.00 | — | 33,761 | — | ↗ |
| 2024-02-06 | Knightly Kevin C | Officer | A-Award | A | Common Stock | 7,241 | 0.00 | — | 9,214 | — | ↗ |
| 2024-02-06 | Bruehlman Ronald E | Officer | A-Award | A | Common Stock | 24,141 | 0.00 | — | 43,845 | — | ↗ |
| 2024-02-06 | BOUSBIB ARI | Director / Officer | A-Award | A | Common Stock | 86,912 | 0.00 | — | 836,504 | — | ↗ |
| 2023-12-01 | Knightly Kevin C | Officer | S-Sale | D | Common Stock | 5,855 | 214.32 | 1.25M | 7,725 | — | ↗ |
| 2023-11-09 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 143 | 0.00 | — | 1,005 | — | ↗ |
| 2023-11-09 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 182 | 0.00 | — | 3,318 | — | ↗ |
| 2023-11-09 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 156 | 0.00 | — | 1,583 | — | ↗ |
| 2023-09-25 | STAUB W RICHARD | Officer | — | D | Common Stock | 0 | 0.00 | — | 25,071 | — | ↗ |
| 2023-09-19 | Panagos Constantinos | Officer | D-Return | D | Common Stock | 18,767 | 208.56 | 3.91M | 14,250 | — | ↗ |
| 2023-08-03 | Bruehlman Ronald E | Officer | F-InKind | D | Common Stock | 2,588 | 216.29 | 559.8K | 19,704 | — | ↗ |
| 2023-07-28 | Cherofsky Keriann | Officer | F-InKind | D | Common Stock | 35 | 226.15 | 7.9K | 864 | — | ↗ |
| 2023-07-19 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 122 | 0.00 | — | 862 | — | ↗ |
| 2023-07-19 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 155 | 0.00 | — | 3,136 | — | ↗ |
| 2023-07-19 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 133 | 0.00 | — | 1,427 | — | ↗ |
| 2023-06-05 | Knightly Kevin C | Officer | S-Sale | D | Common Stock | 5,820 | 201.89 | 1.17M | 0 | — | ↗ |
| 2023-05-26 | Knightly Kevin C | Officer | S-Sale | D | Common Stock | 1 | 198.66 | 198.66 | 0 | — | ↗ |
| 2023-05-10 | Wims Morris Leslie | Director | A-Award | A | Common Stock | 1,063 | 0.00 | — | 2,058 | — | ↗ |
| 2023-05-10 | Stamps Sheila A | Director | A-Award | A | Common Stock | 1,063 | 0.00 | — | 2,058 | — | ↗ |
| 2023-05-10 | LEONARD JOHN M | Director | A-Award | A | Common Stock | 1,063 | 0.00 | — | 12,736 | — | ↗ |
| 2023-05-10 | GOGGINS COLLEEN A | Director | A-Award | A | Common Stock | 1,063 | 0.00 | — | 10,243 | — | ↗ |
| 2023-05-10 | Fasano Jim | Director | A-Award | A | Common Stock | 1,063 | 0.00 | — | 1,063 | — | ↗ |
| 2023-05-10 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 159 | 0.00 | — | 1,294 | — | ↗ |
| 2023-05-10 | Burt Carol | Director | A-Award | A | Common Stock | 1,063 | 0.00 | — | 5,962 | — | ↗ |
| 2023-02-16 | Knightly Kevin C | Officer | S-Sale | D | Common Stock | 2,772 | 225.57 | 625.3K | 1,973 | — | ↗ |
| 2023-02-14 | Sherbet Eric | Officer | S-Sale | D | Common Stock | 1,000 | 230.00 | 230.0K | 17,053 | — | ↗ |
| 2023-02-13 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 118 | 0.00 | — | 593 | — | ↗ |
| 2023-02-13 | Sherbet Eric | Officer | A-Award | A | Stock Appreciation Right | 8,583 | 232.11 | 1.99M | 8,583 | — | ↗ |
| 2023-02-13 | Panagos Constantinos | Officer | A-Award | A | Stock Appreciation Right | 10,300 | 232.11 | 2.39M | 10,300 | — | ↗ |
| 2023-02-13 | Knightly Kevin C | Officer | A-Award | A | Stock Appreciation Right | 6,866 | 232.11 | 1.59M | 6,866 | — | ↗ |
| 2023-02-13 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 150 | 0.00 | — | 2,794 | — | ↗ |
| 2023-02-13 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 130 | 0.00 | — | 1,135 | — | ↗ |
| 2023-02-13 | Cherofsky Keriann | Officer | A-Award | A | Stock Appreciation Right | 1,373 | 232.11 | 318.7K | 1,373 | — | ↗ |
| 2023-02-13 | Bruehlman Ronald E | Officer | A-Award | A | Stock Appreciation Right | 20,600 | 232.11 | 4.78M | 20,600 | — | ↗ |
| 2023-02-13 | BOUSBIB ARI | Director / Officer | A-Award | A | Stock Appreciation Right | 72,102 | 232.11 | 16.74M | 72,102 | — | ↗ |
| 2023-02-11 | Panagos Constantinos | Officer | F-InKind | D | Common Stock | 1,382 | 222.84 | 308.0K | 34,148 | — | ↗ |
| 2023-02-11 | Haas Bernd | Officer | — | — | Stock Appreciation Right | 4,032 | 161.70 | 652.0K | 0 | D | ↗ |
| 2023-02-11 | Cherofsky Keriann | Officer | F-InKind | D | Common Stock | 54 | 222.84 | 12.0K | 899 | — | ↗ |
| 2023-02-11 | Berkshire James G. | Officer | — | — | Stock Appreciation Right | 7,468 | 161.70 | 1.21M | 0 | D | ↗ |
| 2023-02-10 | Sherbet Eric | Officer | F-InKind | D | Common Stock | 326 | 222.84 | 72.6K | 18,053 | — | ↗ |
| 2023-02-10 | Panagos Constantinos | Officer | F-InKind | D | Common Stock | 289 | 222.84 | 64.4K | 35,530 | — | ↗ |
| 2023-02-10 | Knightly Kevin C | Officer | F-InKind | D | Common Stock | 303 | 222.84 | 67.5K | 6,419 | — | ↗ |
| 2023-02-10 | Cherofsky Keriann | Officer | F-InKind | D | Common Stock | 15 | 222.84 | 3.3K | 953 | — | ↗ |
| 2023-02-10 | Bruehlman Ronald E | Officer | F-InKind | D | Common Stock | 614 | 222.84 | 136.8K | 22,292 | — | ↗ |
| 2023-02-10 | BOUSBIB ARI | Director / Officer | F-InKind | D | Common Stock | 3,496 | 222.84 | 779.0K | 749,592 | — | ↗ |
| 2023-02-09 | Sherbet Eric | Officer | F-InKind | D | Common Stock | 317 | 230.31 | 73.0K | 18,379 | — | ↗ |
| 2023-02-09 | Panagos Constantinos | Officer | F-InKind | D | Common Stock | 2,612 | 230.31 | 601.6K | 35,819 | — | ↗ |
| 2023-02-09 | Knightly Kevin C | Officer | F-InKind | D | Common Stock | 311 | 230.31 | 71.6K | 6,722 | — | ↗ |
| 2023-02-09 | Cherofsky Keriann | Officer | F-InKind | D | Common Stock | 60 | 230.31 | 13.8K | 968 | — | ↗ |
| 2023-02-09 | Bruehlman Ronald E | Officer | F-InKind | D | Common Stock | 717 | 230.31 | 165.1K | 22,906 | — | ↗ |
| 2023-02-09 | BOUSBIB ARI | Director / Officer | F-InKind | D | Common Stock | 4,097 | 230.31 | 943.6K | 753,088 | — | ↗ |
| 2023-02-07 | Sherbet Eric | Officer | A-Award | A | Common Stock | 8,745 | 0.00 | — | 21,963 | — | ↗ |
| 2023-02-07 | Panagos Constantinos | Officer | F-InKind | D | Common Stock | 1,341 | 235.84 | 316.3K | 38,431 | — | ↗ |
| 2023-02-07 | Knightly Kevin C | Officer | A-Award | A | Common Stock | 5,829 | 0.00 | — | 9,123 | — | ↗ |
| 2023-02-07 | BOUSBIB ARI | Director / Officer | F-InKind | D | Common Stock | 44,014 | 235.84 | 10.38M | 757,185 | — | ↗ |
| 2022-11-10 | Wims Morris Leslie | Director | A-Award | A | Deferred Shares | 124 | 0.00 | — | 475 | — | ↗ |
| 2022-11-10 | GOGGINS COLLEEN A | Director | A-Award | A | Deferred Shares | 150 | 0.00 | — | 2,644 | — | ↗ |
| 2022-11-10 | DANHAKL JOHN G | Director | A-Award | A | Deferred Shares | 135 | 0.00 | — | 1,005 | — | ↗ |
| 2022-11-01 | Panagos Constantinos | Officer | F-InKind | D | Common Stock | 1,818 | 209.39 | 380.7K | 35,401 | — | ↗ |
| 2022-08-03 | Bruehlman Ronald E | Officer | F-InKind | D | Common Stock | 2,588 | 233.21 | 603.5K | 23,623 | — | ↗ |
Executive team
Top executives
EBIT / Employee
26.1K
Shares Outstanding
169.70M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Ari Bousbib Chairman and Chief Executive Officer | 1.80M | — | 15.75M | 4.53M | 4.97M | 1.08M | 28.13M | 72.09% | ↗ |
| 2 | 2025 | Ronald E. Bruehlman Executive Vice President, Chief Financial Officer | 905.0K | — | 6.75M | 2.25M | 1.29M | 244.8K | 11.44M | 78.64% | ↗ |
| 3 | 2025 | Alistair R. Grenfell President, Commercial Solutions | 629.9K | — | 6.00M | 2.00M | 806.9K | 267.7K | 9.70M | 82.44% | ↗ |
| 4 | 2025 | W. Richard Staub, III President, Research & Development Solutions | 800.0K | — | 5.25M | 1.75M | 943.0K | 86.1K | 8.83M | 79.28% | ↗ |
| 5 | 2025 | Alistair R. Grenfell President, Commercial Solutions Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 665.0K | — | 3.00M | 999.9K | 764.3K | 71.6K | 5.50M | 72.72% | ↗ |
| 6 | 2024 | Ari Bousbib Chairman and Chief Executive Officer | 1.80M | — | 15.75M | 4.49M | 3.60M | 1.09M | 26.73M | 75.71% | ↗ |
| 7 | 2024 | W. Richard Staub, III President, Research & Development Solutions | 800.0K | — | 8.00M | 999.9K | 879.3K | 65.0K | 10.74M | 83.76% | ↗ |
| 8 | 2024 | Ronald E. Bruehlman Executive Vice President, Chief Financial Officer | 905.0K | — | 4.50M | 1.50M | 1.24M | 226.4K | 8.37M | 71.68% | ↗ |
| 9 | 2024 | Bhavik Patel President, Commercial Solutions Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 647.8K | — | 2.06M | 687.5K | 707.4K | 68.8K | 4.17M | 65.88% | ↗ |
| 10 | 2024 | Alistair R. Grenfell President, Commercial Solutions Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 647.8K | — | 2.06M | 687.5K | 707.4K | 68.8K | 4.17M | 65.88% | ↗ |
| 11 | 2024 | Bhavik Patel President, Commercial Solutions | 453.8K | — | 1.50M | 500.0K | 475.5K | 85.3K | 3.01M | 66.34% | ↗ |
| 12 | 2023 | Ari Bousbib Chairman and Chief Executive Officer | 1.80M | — | 16.41M | 4.75M | 4.78M | 1.41M | 29.15M | 72.58% | ↗ |
| 13 | 2023 | Ronald E. Bruehlman Executive Vice President, Chief Financial Officer | 905.0K | — | 4.69M | 1.56M | 1.16M | 249.1K | 8.56M | 72.98% | ↗ |
| 14 | 2023 | Costa Panagos Former President, Research & Development Solutions | 454.7K | — | 3.38M | 781.4K | — | 13.7K | 4.63M | 89.89% | ↗ |
| 15 | 2023 | Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 612.7K | — | 1.95M | 651.1K | 689.7K | 66.6K | 3.97M | 65.54% | ↗ |
| 16 | 2023 | Alistair R. Grenfell President, Commercial Solutions Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 612.7K | — | 1.95M | 651.1K | 689.7K | 66.6K | 3.97M | 65.54% | ↗ |
| 17 | 2023 | Bhavik Patel President, Commercial Solutions Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 612.7K | — | 1.95M | 651.1K | 689.7K | 66.6K | 3.97M | 65.54% | ↗ |
| 18 | 2023 | Kevin C. Knightly President, Corporate Strategy and Enterprise Networks | 578.0K | — | 1.56M | 520.9K | 618.5K | 235.8K | 3.52M | 59.26% | ↗ |
| 19 | 2023 | W. Richard Staub, III President, Research & Development Solutions | 391.7K | — | 781.1K | 260.4K | 455.9K | 38.9K | 1.93M | 54.02% | ↗ |
| 20 | 2022 | Ari Bousbib Chairman and Chief Executive Officer | 1.80M | — | 16.19M | 5.20M | 6.00M | 948.2K | 30.14M | 70.98% | ↗ |
| 21 | 2022 | Ronald E. Bruehlman Executive Vice President, Chief Financial Officer | 895.4K | — | 4.63M | 1.48M | 1.40M | 211.7K | 8.62M | 70.89% | ↗ |
| 22 | 2022 | Costa Panagos Former President, Research & Development Solutions | 581.9K | — | 2.52M | 494.8K | 736.0K | 48.4K | 4.38M | 68.82% | ↗ |
| 23 | 2022 | Costa Panagos President, Research & Development Solutions | 581.9K | — | 2.52M | 494.8K | 736.0K | 48.4K | 4.38M | 68.82% | ↗ |
| 24 | 2022 | Kevin C. Knightly President, Corporate Strategy and Enterprise Networks Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 562.1K | — | 1.73M | 556.6K | 701.9K | 61.1K | 3.62M | 63.36% | ↗ |
| 25 | 2022 | Bhavik Patel President, Commercial Solutions Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 562.1K | — | 1.73M | 556.6K | 701.9K | 61.1K | 3.62M | 63.36% | ↗ |
| 26 | 2022 | Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 562.1K | — | 1.73M | 556.6K | 701.9K | 61.1K | 3.62M | 63.36% | ↗ |
| 27 | 2022 | Costa Panagos President, Research & Development Solutions Kevin C. Knightly President, Corporate Strategy and Enterprise Networks | 572.3K | — | 1.54M | 494.8K | 700.7K | 99.3K | 3.41M | 59.75% | ↗ |
| 28 | 2022 | Kevin C. Knightly President, Corporate Strategy and Enterprise Networks | 572.3K | — | 1.54M | 494.8K | 700.7K | 99.3K | 3.41M | 59.75% | ↗ |
| 29 | 2022 | W. Richard Staub, III President, Research & Development Solutions | 335.8K | — | 1.16M | 371.1K | 350.0K | 61.8K | 2.28M | 67.14% | ↗ |
| 30 | 2021 | Ari Bousbib Chairman and Chief Executive Officer | 1.80M | — | 14.11M | 4.43M | 7.20M | 1.08M | 28.62M | 64.77% | ↗ |
| 31 | 2021 | Ronald E. Bruehlman Executive Vice President, Chief Financial Officer | 872.9K | — | 3.92M | 1.23M | 1.74M | 150.1K | 7.91M | 65.05% | ↗ |
| 32 | 2021 | W. Richard Staub, III President, Research & Development Solutions | 614.1K | — | 1.41M | 442.5K | 1.03M | 70.0K | 3.56M | 52.01% | ↗ |
| 33 | 2021 | Ronald E. Bruehlman Executive Vice President, Chief Financial Officer W. Richard Staub, III President, Research & Development Solutions | 614.1K | — | 1.41M | 442.5K | 1.03M | 70.0K | 3.56M | 52.01% | ↗ |
| 34 | 2021 | W. Richard Staub, III President, Research & Development Solutions Kevin C. Knightly President, Technology & Commercial Solutions | 558.3K | — | 1.18M | 368.8K | 849.3K | 136.1K | 3.09M | 50.01% | ↗ |
| 35 | 2021 | Kevin C. Knightly President, Corporate Strategy and Enterprise Networks | 558.3K | — | 1.18M | 368.8K | 849.3K | 136.1K | 3.09M | 50.01% | ↗ |
| 36 | 2021 | Costa Panagos President, Research & Development Solutions Kevin C. Knightly President, Corporate Strategy and Enterprise Networks | 558.3K | — | 1.18M | 368.8K | 849.3K | 136.1K | 3.09M | 50.01% | ↗ |
| 37 | 2021 | Kevin C. Knightly President, Corporate Strategy and Enterprise Networks Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 532.9K | — | 1.25M | 393.4K | 776.5K | 60.3K | 3.02M | 54.60% | ↗ |
| 38 | 2021 | Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 532.9K | — | 1.25M | 393.4K | 776.5K | 60.3K | 3.02M | 54.60% | ↗ |
| 39 | 2021 | Kevin C. Knightly President, Technology & Commercial Solutions Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 532.9K | — | 1.25M | 393.4K | 776.5K | 60.3K | 3.02M | 54.60% | ↗ |
| 40 | 2020 | Ari Bousbib Chairman and Chief Executive Officer | 1.64M | — | 8.32M | 7.60M | 6.52M | 1.49M | 25.58M | 62.23% | ↗ |
| 41 | 2020 | Ronald E. Bruehlman Executive Vice President, Chief Financial Officer | 358.3K | — | 2.70M | — | 668.8K | 201.3K | 3.93M | 68.73% | ↗ |
| 42 | 2020 | Ronald E. Bruehlman Executive Vice President, Chief Financial Officer W. Richard Staub, III President, Research & Development Solutions | 584.8K | — | 831.6K | 760.0K | 806.0K | 62.3K | 3.04M | 52.27% | ↗ |
| 43 | 2020 | Kevin C. Knightly President, Corporate Strategy and Enterprise Networks Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 507.5K | — | 831.6K | 760.0K | 677.4K | 51.1K | 2.83M | 56.29% | ↗ |
| 44 | 2020 | Kevin C. Knightly President, Technology & Commercial Solutions Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 507.5K | — | 831.6K | 760.0K | 677.4K | 51.1K | 2.83M | 56.29% | ↗ |
| 45 | 2020 | Costa Panagos President, Research & Development Solutions Kevin C. Knightly President, Corporate Strategy and Enterprise Networks | 531.7K | — | 554.4K | 506.6K | 660.4K | 297.3K | 2.55M | 41.60% | ↗ |
| 46 | 2020 | W. Richard Staub, III President, Research & Development Solutions Kevin C. Knightly President, Technology & Commercial Solutions | 531.7K | — | 554.4K | 506.6K | 660.4K | 297.3K | 2.55M | 41.60% | ↗ |
| 47 | 2020 | Eric M. Sherbet Executive Vice President, General Counsel and Secretary Michael R. McDonnell Former Executive Vice President, Chief Financial Officer | 371.3K | — | 887.1K | 810.6K | — | 15.7K | 2.08M | 81.44% | ↗ |
| 48 | 2019 | Ari Bousbib Chairman and Chief Executive Officer | 1.68M | — | 6.60M | 6.03M | 6.60M | 1.23M | 22.14M | 57.03% | ↗ |
| 49 | 2019 | Eric M. Sherbet Executive Vice President, General Counsel and Secretary Michael R. McDonnell Former Executive Vice President, Chief Financial Officer | 660.0K | — | 824.9K | 753.3K | 645.0K | 64.9K | 2.95M | 53.53% | ↗ |
| 50 | 2019 | Ronald E. Bruehlman Executive Vice President, Chief Financial Officer W. Richard Staub, III President, Research & Development Solutions | 596.1K | — | 660.0K | 602.7K | 720.0K | 62.5K | 2.64M | 47.81% | ↗ |
| 51 | 2019 | W. Richard Staub, III President, Research & Development Solutions Kevin C. Knightly President, Technology & Commercial Solutions | 542.5K | — | 660.0K | 602.7K | 600.0K | 208.6K | 2.61M | 48.31% | ↗ |
| 52 | 2019 | Kevin C. Knightly President, Technology & Commercial Solutions Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 515.0K | — | 660.0K | 602.7K | 550.0K | 41.5K | 2.37M | 53.29% | ↗ |
| 53 | 2018 | Ari Bousbib Chairman, Chief Executive Officer & President | 1.60M | — | 3.91M | 3.64M | 6.30M | 1.01M | 16.46M | 45.86% | ↗ |
| 54 | 2018 | Ari Bousbib Chairman and Chief Executive Officer | 1.60M | — | 3.91M | 3.64M | 6.30M | 1.01M | 16.46M | 45.86% | ↗ |
| 55 | 2018 | Michael R. McDonnell Executive Vice President, Chief Financial Officer | 650.0K | — | 651.8K | 606.2K | 600.0K | 58.6K | 2.57M | 49.01% | ↗ |
| 56 | 2018 | Eric M. Sherbet Executive Vice President, General Counsel and Secretary Michael R. McDonnell Former Executive Vice President, Chief Financial Officer | 650.0K | — | 651.8K | 606.2K | 600.0K | 58.6K | 2.57M | 49.01% | ↗ |
| 57 | 2018 | James H. Erlinger III Former Executive Vice President, General Counsel and Secretary | 122.5K | — | 59.7K | 53.8K | — | 2.17M | 2.40M | 4.72% | ↗ |
| 58 | 2018 | Ronald E. Bruehlman Executive Vice President, Chief Financial Officer W. Richard Staub, III President, Research & Development Solutions | 578.6K | — | 521.5K | 485.0K | 615.0K | 43.0K | 2.24M | 44.87% | ↗ |
| 59 | 2018 | W. Richard Staub, III President, Research & Development Solutions | 578.6K | — | 521.5K | 485.0K | 615.0K | 43.0K | 2.24M | 44.87% | ↗ |
| 60 | 2018 | W. Richard Staub, III President, Research & Development Solutions Kevin C. Knightly President, Technology & Commercial Solutions | 517.5K | — | 521.5K | 485.0K | 575.0K | 91.2K | 2.19M | 45.95% | ↗ |
| 61 | 2018 | Kevin C. Knightly President, Technology & Commercial Solutions | 517.5K | — | 521.5K | 485.0K | 575.0K | 91.2K | 2.19M | 45.95% | ↗ |
| 62 | 2018 | Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 415.8K | — | 294.7K | 275.0K | 350.0K | 63.9K | 1.40M | 40.71% | ↗ |
| 63 | 2018 | Kevin C. Knightly President, Technology & Commercial Solutions Eric M. Sherbet Executive Vice President, General Counsel and Secretary | 415.8K | — | 294.7K | 275.0K | 350.0K | 63.9K | 1.40M | 40.71% | ↗ |
| 64 | 2017 | Ari Bousbib Chairman, Chief Executive Officer & President | 1.60M | — | 26.39M | 2.98M | 6.00M | 1.05M | 38.03M | 77.25% | ↗ |
| 65 | 2017 | Michael R. McDonnell Executive Vice President, Chief Financial Officer | 650.0K | — | 2.04M | 497.4K | 600.0K | 475.3K | 4.26M | 59.53% | ↗ |
| 66 | 2017 | Kevin C. Knightly President, Technology & Commercial Solutions | 487.5K | — | 378.1K | 348.2K | 600.0K | 175.5K | 1.99M | 36.51% | ↗ |
| 67 | 2017 | W. Richard Staub, III President, Research & Development Solutions | 555.0K | — | 378.1K | 348.2K | 550.0K | 35.8K | 1.87M | 38.90% | ↗ |
| 68 | 2017 | James H. Erlinger III Executive Vice President, General Counsel | 482.5K | — | 297.0K | 273.6K | — | 43.6K | 1.10M | 52.03% | ↗ |
| 69 | 2017 | James H. Erlinger III Former Executive Vice President, General Counsel and Secretary | 482.5K | — | 297.0K | 273.6K | — | 43.6K | 1.10M | 52.03% | ↗ |
| 70 | 2016 | Thomas H. Pike Former, Vice Chairman and President, Research & Development Solutions | 1.06M | — | 10.31M | 2.61M | — | 6.64M | 20.61M | 62.69% | ↗ |
| 71 | 2016 | Ari Bousbib Chairman, Chief Executive Officer & President | 390.1K | — | — | — | 6.00M | 249.8K | 6.64M | 0.00% | ↗ |
| 72 | 2016 | Kevin K. Gordon Former, Executive Vice President and Chief Operating Officer | 509.1K | — | 1,000.0K | 830.5K | — | 2.92M | 5.26M | 34.81% | ↗ |
| 73 | 2016 | Michael R. McDonnell Executive Vice President, Chief Financial Officer | 650.0K | 500.0K | 500.0K | 414.4K | 600.0K | 79.0K | 2.74M | 33.33% | ↗ |
| 74 | 2016 | W. Richard Staub, III President, Research & Development Solutions | 485.9K | — | 899.9K | 124.0K | 253.3K | 33.7K | 1.80M | 56.98% | ↗ |
| 75 | 2016 | James H. Erlinger III Former Executive Vice President, General Counsel and Secretary | 468.3K | — | 400.0K | 331.1K | 400.0K | 39.8K | 1.64M | 44.60% | ↗ |
| 76 | 2016 | James H. Erlinger III Executive Vice President, General Counsel | 468.3K | — | 400.0K | 331.1K | 400.0K | 39.8K | 1.64M | 44.60% | ↗ |
| 77 | 2016 | Kevin C. Knightly President, Information & Technology Solutions | 119.4K | — | — | — | 500.0K | 19.4K | 638.8K | 0.00% | ↗ |
| 78 | 2016 | Kevin C. Knightly President, Technology & Commercial Solutions | 119.4K | — | — | — | 500.0K | 19.4K | 638.8K | 0.00% | ↗ |
| 79 | 2015 | Thomas H. Pike Chief Executive Officer and Director | 1.04M | — | 625.0K | 2.37M | 1.23M | 3.5K | 5.26M | 56.87% | ↗ |
| 80 | 2015 | Thomas H. Pike Former, Vice Chairman and President, Research & Development Solutions | 1.04M | — | 625.0K | 2.37M | 1.23M | 3.5K | 5.26M | 56.87% | ↗ |
| 81 | 2015 | Kevin K. Gordon Executive Vice President and Chief Operating Officer | 612.9K | — | 500.0K | 1.43M | 678.0K | 13.8K | 3.23M | 59.65% | ↗ |
| 82 | 2015 | Kevin K. Gordon Former, Executive Vice President and Chief Operating Officer | 612.9K | — | 500.0K | 1.43M | 678.0K | 13.8K | 3.23M | 59.65% | ↗ |
| 83 | 2015 | Michael R. McDonnell Executive Vice President, Chief Financial Officer | 27.1K | 500.0K | 2.50M | — | — | — | 3.03M | 82.59% | ↗ |
| 84 | 2015 | Michael R. McDonnell Executive Vice President and Chief Financial Officer | 27.1K | 500.0K | 2.50M | — | — | — | 3.03M | 82.59% | ↗ |
| 85 | 2015 | Dr. Dennis B. Gillings, CBE Executive Chairman | 800.0K | — | — | — | 784.0K | 38.2K | 1.62M | 0.00% | ↗ |
| 86 | 2015 | James H. Erlinger III Executive Vice President, General Counsel | 435.0K | — | 200.0K | 571.4K | 322.0K | 17.0K | 1.55M | 49.92% | ↗ |
| 87 | 2014 | Michael I. Mortimer Former Executive Vice President, Human Resources and Corporate Administration | 265.0K | 350.0K | — | — | — | 2.22M | 2.83M | 0.00% | ↗ |
| 88 | 2014 | Thomas H. Pike Chief Executive Officer and Director | 1.04M | — | — | — | 1.60M | 24.4K | 2.66M | 0.00% | ↗ |
| 89 | 2014 | Thomas H. Pike Former, Vice Chairman and President, Research & Development Solutions | 1.04M | — | — | — | 1.60M | 24.4K | 2.66M | 0.00% | ↗ |
| 90 | 2014 | Thomas H. Pike Chief Executive Officer and Director | 1.04M | — | — | — | 1.60M | 24.4K | 2.66M | 0.00% | ↗ |
| 91 | 2014 | Kevin K. Gordon Executive Vice President and Chief Financial Officer | 580.0K | — | 301.6K | 912.5K | 819.8K | 13.0K | 2.63M | 46.22% | ↗ |
| 92 | 2014 | Kevin K. Gordon Former, Executive Vice President and Chief Operating Officer | 580.0K | — | 301.6K | 912.5K | 819.8K | 13.0K | 2.63M | 46.22% | ↗ |
| 93 | 2014 | Kevin K. Gordon Executive Vice President and Chief Operating Officer | 580.0K | — | 301.6K | 912.5K | 819.8K | 13.0K | 2.63M | 46.22% | ↗ |
| 94 | 2014 | Dr. Dennis B. Gillings, CBE Executive Chairman | 800.0K | — | — | — | 1.00M | 44.1K | 1.84M | 0.00% | ↗ |
| 95 | 2014 | Dennis B. Gillings, CBE Executive Chairman | 800.0K | — | — | — | 1.00M | 44.1K | 1.84M | 0.00% | ↗ |
| 96 | 2014 | James H. Erlinger III Executive Vice President, General Counsel | 434.4K | — | 124.5K | 380.6K | 328.8K | 31.7K | 1.30M | 38.85% | ↗ |
| 97 | 2013 | John D. Ratliff Former President, Chief Operating Officer and Director | 676.3K | 650.0K | — | 2.25M | — | 3.21M | 6.79M | 33.17% | ↗ |
| 98 | 2013 | Kevin K. Gordon Executive Vice President and Chief Financial Officer | 570.0K | 500.0K | 500.0K | 1.83M | 700.0K | 48.8K | 4.15M | 56.21% | ↗ |
| 99 | 2013 | Kevin K. Gordon Executive Vice President and Chief Operating Officer | 570.0K | 500.0K | 500.0K | 1.83M | 700.0K | 48.8K | 4.15M | 56.21% | ↗ |
| 100 | 2013 | Michael I. Mortimer Former Executive Vice President, Human Resources and Corporate Administration | 526.3K | — | — | 1.42M | 550.0K | 787.6K | 3.28M | 43.18% | ↗ |
| 101 | 2013 | Michael I. Mortimer Executive Vice President, Human Resources and Corporate Administration | 526.3K | — | — | 1.42M | 550.0K | 787.6K | 3.28M | 43.18% | ↗ |
| 102 | 2013 | Thomas H. Pike Chief Executive Officer and Director | 1.04M | — | — | — | 1.50M | 50.8K | 2.59M | 0.00% | ↗ |
| 103 | 2013 | Thomas H. Pike Chief Executive Officer and Director | 1.04M | — | — | — | 1.50M | 50.8K | 2.59M | 0.00% | ↗ |
| 104 | 2013 | Dr. Dennis B. Gillings, CBE Executive Chairman | 871.2K | — | — | — | 1.00M | 63.3K | 1.93M | 0.00% | ↗ |
| 105 | 2013 | Dennis B. Gillings, CBE Executive Chairman | 871.2K | — | — | — | 1.00M | 63.3K | 1.93M | 0.00% | ↗ |
| 106 | 2012 | Thomas H. Pike Chief Executive Officer and Director | 670.5K | 916.7K | — | 7.13M | — | 155.3K | 8.87M | 80.36% | ↗ |
| 107 | 2012 | Dennis B. Gillings, CBE Executive Chairman | 1.00M | 1.41M | — | 2.36M | 1.50M | 146.7K | 6.41M | 36.75% | ↗ |
| 108 | 2012 | John D. Ratliff Former President, Chief Operating Officer and Director | 650.0K | 1.91M | — | 2.04M | 900.0K | 63.0K | 5.57M | 36.68% | ↗ |
| 109 | 2012 | Michael I. Mortimer Executive Vice President, Human Resources and Corporate Administration | 500.0K | 819.5K | — | 1.77M | 553.4K | 1.60M | 5.24M | 33.81% | ↗ |
| 110 | 2012 | Kevin K. Gordon Executive Vice President and Chief Financial Officer | 500.0K | 334.6K | — | 1.24M | 553.4K | 55.8K | 2.68M | 46.15% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ari Bousbib | Chief Executive Officer & Chairman | 7M | male |
| Michael J. Fedock | Executive Vice President & Chief Financial Officer | 2M | male |
| W. Richard Staub | President of Research & Development Solutions | 2M | male |
| Alistair Grenfell | President of Commercial Solutions | 2M | male |
| Eric Sherbet | Executive Vice President, General Counsel & Secretary | 2M | male |
| James G. Berkshire | Executive Vice President of Global Infrastructure & Operations | — | male |
| Jeffrey A. Spaeder | Chief Medical & Scientific Officer | — | — |
| Keriann Cherofsky | Senior Vice President, Corporate Controller & Chief Accounting Officer | — | female |
| Kerri Joseph | Senior VP of Investor Relations & Treasurer | — | — |
| Cynthia L. Verst | President of Design & Delivery Innovation | — | — |
| Trudy Stein | Chief Human Resources Officer & Executive Vice President | — | female |
| Duane Sachs | Senior Vice President of Corporate Development | — | male |
ESG Rating
ESG Score History MEDICAL - DIAGNOSTICS & RESEARCH
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-12-29 | 2026-01-16 | Markwayne Mullin | OK | Joint | Purchase | $15,001 - $50,000 | ↗ |
| 2025-10-02 | 2025-11-15 | John Boozman | AR | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2025-10-02 | 2025-11-15 | John Boozman | AR | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-02-13 | 2025-02-27 | Markwayne Mullin | OK | Joint | Purchase | $15,001 - $50,000 | ↗ |
| 2024-08-20 | 2024-09-19 | Markwayne Mullin | OK | Joint | Purchase | $15,001 - $50,000 | ↗ |
| 2019-02-28 | 2019-03-18 | John Reed | RI | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2019-02-04 | 2019-03-01 | John Reed | RI | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2018-03-09 | 2018-03-12 | John Reed | RI | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-16 | 2026-04-06 | Kevin Hern | OK01 | Joint | Sale | $50,001 - $100,000 | ↗ |
| 2025-09-29 | 2025-10-03 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-05-15 | 2025-06-02 | Rob Bresnahan | PA08 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-04-08 | 2025-05-08 | Rob Bresnahan | PA08 | — | Purchase | $15,001 - $50,000 | ↗ |
| 2025-02-25 | 2025-03-28 | Rob Bresnahan | PA08 | — | Sale | $1,001 - $15,000 | ↗ |
| 2024-02-13 | 2024-03-06 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-11-03 | 2023-12-06 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-10-31 | 2023-11-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2023-10-02 | 2023-11-08 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-05-23 | 2023-06-12 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-05-19 | 2023-06-12 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-05-09 | 2023-05-26 | Susie Lee | NV03 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2023-04-20 | 2023-05-12 | Susie Lee | NV03 | Joint | Sale (Partial) | $1,001 - $15,000 | ↗ |
| 2023-04-10 | 2023-05-19 | Daniel Goldman | NY10 | — | Sale | $15,001 - $50,000 | ↗ |
| 2023-03-14 | 2023-04-07 | Ro Khanna | CA17 | Spouse | Sale | $15,001 - $50,000 | ↗ |
| 2023-01-09 | 2023-02-07 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-12-06 | 2023-01-03 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-11-03 | 2022-12-06 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-08-23 | 2022-09-08 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2022-07-20 | 2022-07-28 | Diana Harshbarger | TN01 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IQV
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
